New publication confirms clinical efficiency and patient safety of INTERCEPT™ Blood System for platelets
Large Austrian Medical Centre publishes study results on component utilization and patient safety after adoption of platelet pathogen inactivation.
The Medical University Hospital in Innsbruck has evaluated the influence of the INTERCEPT™ Blood System for platelets on component utilization and patient safety. The effectiveness of conventional vs. INTERCEPT™-treated platelets was analyzed during two 21-month periods before and after implementation of pathogen inactivation.
Results of the study were published recently in Vox Sanguinis - The Internal Journal of Transfusion Medicine.